-
A combination therapy with aspirin and low-dose rivaroxaban appears to be more effective in the secondary prevention of cardiovascular events than aspirin monotherapy.
-
With a modified folfirinox regimen, patients with non-metastatic pancreatic ductal carcinoma in adjuvant chemotherapy achieved a survival of 54.5 months compared to the previous gemcitabine standard of 35 months.
-
Recent data has shown that once-daily oral 4 mg of baricitinib for patients with systemic lupus erythematosus (SLE) who receive standard background therapy, is associated with significant clinical improvements compared to placebo.
-
Immunotherapy with the PD1 inhibitor pembrolizumab acts as first-line therapy in patients with advanced NSCLC and PD-L1 expression ≥ 1% better than standard chemotherapy. Patients lived 4 to 8 months longer in the median, with fewer side effects.
-
The results of a Scottish cluster-randomized study on Type-2 diabetes indicate that the illness could be reversed without anti-diabetic medicines.
-
Biosimilars use has taken off in the past few years and is expected to increase further. Recent findings add to the increasing evidence that switching from originator to bDMARDs is safe and efficacious.
-
Blue-181 molecule acts on spinal cord pain receptors instead of the brain, and arguably produces no narcotic or addiction side effects
-
Treatment with sunitinib alone was not inferior to nephrectomy followed by sunitinib in patients with advanced renal cell carcinoma and intermediate to high risk in effect on overall survival.
-
Dose-related NSAIDs with TNFi use in ankylosing spondylitis patients have a synergistic effect in slowing radiographic progression. The greatest effect is seen in those using both high-dose NSAIDs and TNFi.
-
In May 2018, Philips’ ICS-CERT unit released tips on the safety issues that could breach its Brilliance CT scanner. How severe and which other safety gaps are there in medical imaging systems?
-
At the last cardiology congress of the American Heart Association (AHA), new high blood pressure guidelines were presented. Values of 120/80 mmHg and above have been deemed high in the USA.
-
Vinorelbine and low-dose cyclophosphamide therapies significantly increase overall 5-year survival in high-risk children with RMS, from 73.3% without maintenance therapy to 86.5%
-
Infliximab, etanercept, adalimumab, ixekizumab, ustekinumab, secukinumab, and certolizumab pegol provided improvements in health assessment questionnaire-disability index scores from baseline.
-
Tumors with high microsatellite instability (MSI) are often associated with Lynch syndrome. Tumor patients with high MSI, and mutations in DNA mismatch repair genes should be checked for the syndrome.
-
Tapering csDMARDs or anti-TNF showed no significant differences in flare ratios, disease activity, functional ability and quality of life between both tapering strategies in the first 12 months of follow-up.
-
A study concludes that if a mean recurrence score of 11-25 is found in women with early hormone-receptor-positive HER2-negative breast carcinoma without axillary lymph nodes using a 21 gene expression test, adjuvant chemotherapy may be dispensed with.
-
Paris is seeing an exponential population explosion of rats. A local elected official has taken on the internet and the public to tackle the issue.
-
Data from the Dutch COBRA study show a normalization of rheumatoid arthritis (RA) mortality when compared to the general population after 23 years of follow-up. These findings confirm that early, intensive treatment of RA offers long-term benefits and strongly suggest these benefits include normalization of mortality.
-
Unprecedented 4-year survival rates can be achieved with first-line therapy in children and adolescents with T-cell Acute Lymphoblastic Leukemia (T-ALL) with the additional administration of nelarabine to COG’s augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy regime.
-
Can conventional rheumatism drugs halve the risk of dementia in patients with rheumatoid arthritis? A large cohort study data hints at this and gives a particular protective potential for methotrexate.
